vTv Therapeutics (VTVT) Return on Capital Employed (2015 - 2026)

vTv Therapeutics has disclosed Return on Capital Employed across 12 years of filings, most recently posting 3.48% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 3.48%, up 7779.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 3.48% (up 7779.0% YoY), and the FY2025 annual result was 57.12%, up 6723.0% from the prior year.
• Return on Capital Employed came in at 3.48% for Q1 2026 at vTv Therapeutics, up from 37.26% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 3.48% in Q1 2026 to a low of 1084.27% in Q4 2023.
• The 5-year median for Return on Capital Employed is 94.86% (2022), against an average of 163.96%.
• Across the five-year window, Return on Capital Employed slumped 99975 bps in 2023 and soared 101619 bps in 2024, its largest moves.
• vTv Therapeutics' Return on Capital Employed stood at 84.52% in 2022, then slumped by 1183 bps to 1084.27% in 2023, then soared by 94 bps to 68.08% in 2024, then jumped by 45 bps to 37.26% in 2025, then soared by 91 bps to 3.48% in 2026.
• The last three Return on Capital Employed figures came in at 3.48% (Q1 2026), 37.26% (Q4 2025), and 56.46% (Q3 2025), per Business Quant data.